Primary Cutaneous T-Cell Non-Hodgkin Lymphoma clinical trials in New York
10 active Primary Cutaneous T-Cell Non-Hodgkin Lymphoma trials with a site in New York. Describe your situation to see which ones look like a fit.
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
- A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
- A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- Amping up With PemJAK
- Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
- A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- A Study of Ruxolitinib and Duvelisib in People With Lymphoma
- Tissue Repository: CTCL Collection Protocol
- StrataCTX® as a Steroid Sparing Device
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.